Takeda

Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run
Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run
Endpoints
Molecular Templates
Takeda
Multiple Myeloma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Flag link:
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
Bloomberg
Takeda
Shire
M&A
Xiidra
Flag link:
Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
Takeda shuttering Chicago complex with 1,000 staffers in lead-up to Shire merger
Endpoints
Takeda
Shire
M&A
layoffs
Flag link:
Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal
Traditionalists at Takeda spark a family feud with CEO Christophe Weber over his $62B Shire takeover deal
Endpoints
Takeda
Pharma CEOs
Christophe Weber
Shire
M&A
Flag link:
Shire Secures FDA Approval for HAE Drug Lanadelumab
Shire Secures FDA Approval for HAE Drug Lanadelumab
BioSpace
Shire
Takeda
HAE
hereditary angiodema
Takhzyro
lanadelumab
FDA
Flag link:
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
RAPS.org
FDA
JNJ
Janssen
Lundbeck
Takeda
major depressive disorder
drug development
Flag link:
Shire dodges pricing questions as lanadelumab’s big day nears
Shire dodges pricing questions as lanadelumab’s big day nears
EP Vantage
Takeda
HAE
lanadelumab
FDA
Flag link:
Third Rock and Takeda Fund $140 Million Startup to Create Regenerative Therapies for Liver Diseases
Third Rock and Takeda Fund $140 Million Startup to Create Regenerative Therapies for Liver Diseases
CP Wire
Ambys Medicines
Takeda
Third Rock
Flag link:
Takeda announces new series of non-core-asset sales
Takeda announces new series of non-core-asset sales
GoinPharma
Takeda
Shire
M&A
Flag link:
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs — but is it worth $62B?
Endpoints
Takeda
Shire
M&A
Flag link:
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in
pH-Dependent Drug-Drug Interactions: Novartis, Merck, Gilead and More Weigh in
RAPS.org
Novartis
Merck
GSK
Gilead Sciences
Bayer
AstraZeneca
AbbVie
Takeda
FDA
DDIs
drug-drug interactions
proton pump inhibitors
Flag link:
More Positive Results For Takeda's Alunbrig Acquisition
More Positive Results For Takeda's Alunbrig Acquisition
CP Wire
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Flag link:
More Positive Results For Takeda's Alunbrig Acquisition
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Flag link:
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
CP Wire
Takeda
vedolizumab
ulcerative colitis
Entyvio
Flag link:
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Takeda
Entyvio
ulcerative colitis
Chron's Disease
Flag link:
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
CP Wire
Takeda
Ovid Therapeutics
TAK-935/OV935
Flag link:
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Takeda
Ovid Therapeutics
developmental epileptic encephalopathies
Flag link:
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology
BioSpace
Presage Biosciences
Takeda
Celgene
cancer
diagnostics
Flag link:
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
Takeda's Ninlaro Met Primary Endpoint in Ph III Trial In Patients with Multiple Myeloma Post Stem Cell Transplant
CP Wire
Takeda
Ninlaro
Multiple Myeloma
Flag link:

Pages